{{expand|time=2017-04-03T09:27:46+00:00}}
{{drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 390594267
| IUPAC_name = 2-(2-methyl-5-nitro-1''H''-imidazol-1-yl)ethanol
| image = Metronidazol.svg
| image2 = Metronidazole 3D 1w3r.png
<!--Clinical data-->
| tradename = Flagyl
| Drugs.com = {{drugs.com|monograph|metronidazole}}
| pregnancy_US = B
| pregnancy_AU = B2
| legal_AU = S4
| legal_CA = Rx-only
| legal_UK = POM
| legal_US = Rx-only
| routes_of_administration = 口服、[[外用|外用]]、[[栓剂|栓剂]]、[[靜脈注射|靜脈注射]]、[[陰道|陰道]]
<!--Pharmacokinetic data-->
| bioavailability = 口服：80%<br>栓劑：60-80%<br>陰道：20-25%<ref name = MSR>{{cite web|title=Flagyl, Flagyl ER (metronidazole) dosing, indications, interactions, adverse effects, and more|work=Medscape Reference|publisher=WebMD|accessdate=3 April 2014|url=http://reference.medscape.com/drug/flagyl-metronidazole-342566#showall}}</ref><ref name = MD>{{cite web|title=Metronidazole|work=Martindale: The Complete Drug Reference|publisher=Pharmaceutical Press|date=14 January 2014|accessdate=3 April 2014|url=http://www.medicinescomplete.com/mc/martindale/current/ms-16893-c.htm|editor=Brayfield, A}}</ref>
| protein_bound = 20%<ref name = MSR/><ref name = MD/>
| metabolism = [[肝臟|肝臟]]<ref name = MSR/><ref name = MD/>
| elimination_half-life = 8小時<ref name = MSR/><ref name = MD/>
| excretion = Urine (77%), faeces (14%)<ref name = MSR/><ref name = MD/>
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 443-48-1
| ATC_prefix = A01
| ATC_suffix = AB17
| ATC_supplemental = , {{ATC|D06|BX01}}, {{ATC|G01|AF01}}, {{ATC|J01|XD01}}, {{ATC|P01|AB01}}, {{ATCvet|P51|AA01}}
| PubChem = 4173
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank = DB00916
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4029
| NIAID_ChemDB = 007953
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = 140QMO216E
| KEGG_Ref = {{keggcite|changed|kegg}}
| KEGG = D00409
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 6909
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 137
<!--Chemical data-->
| C=6 | H=9 | N=3 | O=3
| molecular_weight = 171.15 g/mol
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C6H9N3O3/c1-5-7-4-6(9(11)12)8(5)2-3-10/h4,10H,2-3H2,1H3
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = VAOCPAMSLUNLGC-UHFFFAOYSA-N
| melting_point = 159
| melting_high = 163
}}
<!-- Definition and uses -->

'''甲硝唑'''（Metronidazole，MNZ），目前多以'''咪唑尼達'''（Flagyl）的商品名流通，是一種[[抗生素|抗生素]]和{{le|抗原蟲劑|antiprotozoal medication}}<ref name=AHFS2015/>。常單獨或和其他抗生素一起使用，作為治療[[骨盆腔炎|骨盆腔炎]]、[[心內膜炎|心內膜炎]]與[[細菌性陰道炎|細菌性陰道炎]]的藥物<ref name=AHFS2015/>。在對抗[[麥地那龍線蟲病|麥地那龍線蟲病]]、{{le|梨形鞭毛蟲症|giardiasis}}、[[陰道滴蟲|陰道滴蟲]]，和{{le|阿米巴病|amebiasis}}上更有顯著效果。針對首次發病的輕中度[[困難梭狀芽孢桿菌|困難梭狀芽孢桿菌]]結腸炎患者，此藥更是第一優先藥物<ref>{{cite journal|last1=Cohen|first1=Stuart H.|last2=Gerding|first2=Dale N.|last3=Johnson|first3=Stuart|last4=Kelly|first4=Ciaran P.|last5=Loo|first5=Vivian G.|last6=McDonald|first6=L. Clifford|last7=Pepin|first7=Jacques|last8=Wilcox|first8=Mark H.|title=Clinical Practice Guidelines for Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA)|journal=Infection Control and Hospital Epidemiology|date=May 2010|volume=31|issue=5|pages=431–455|doi=10.1086/651706|pmid=20307191}}</ref>。甲硝唑可藉由口服、製成乳膏，或經靜脈注射來進行治療<ref name=AHFS2015>{{cite web|title=Metronidazole|url=http://www.drugs.com/monograph/metronidazole.html|publisher=The American Society of Health-System Pharmacists|accessdate=Jul 31,15}}</ref>。

<!-- Side effects -->
常見的副作用包含[[噁心|噁心]]、口腔金屬味感、失去食慾還有頭痛<ref name=AHFS2015/>，少數病患則可能會[[癲癇發作|癲癇發作]]或產生藥物過敏<ref name=AHFS2015/>。對於懷孕初期的孕婦，不應給予甲硝唑，但若是到了懷孕後期則沒有這個顧忌<ref name=AHFS2015/>。特別注意的是，正在[[哺乳|哺乳]]的婦女也不建議使用<ref name=AHFS2015/>。

<!-- History, society and culture -->
甲硝唑首先在1960年的法國開始被廣泛使用<ref>{{cite book|last1=Corey|first1=E.J.|title=Drug discovery practices, processes, and perspectives|date=2013|publisher=John Wiley & Sons|location=Hoboken, N.J.|isbn=9781118354469|page=27|url=https://books.google.ca/books?id=E6Dv5XsXU-IC&pg=PA27}}</ref> ，它同時也名列[[世界衛生組織基本藥物標準清單|世界衛生組織基本藥物標準清單]]中。更是基礎醫療上必備的藥物<ref name=WHOEssen>{{cite web|title=WHO Model List of Essential Medicines|url=http://apps.who.int/iris/bitstream/10665/93142/1/EML_18_eng.pdf?ua=1|work=World Health Organization|accessdate=22 April 2014|date=October 2013|format=PDF}}</ref>，在世界上大部分的國家都能輕易取得<ref>{{cite web|author1=Schmid G|title=Trichomoniasis treatment in women|url=http://apps.who.int/rhl/rti_sti/gscom/en/|accessdate=1 August 2015|date=28 July 2003}}</ref>。此藥物的價格非常平易近人，每顆平均價格介於0.01到0.1美元間<ref>{{cite web|title=Sources and Prices of Selected Medicines and Diagnostics for People Living with HIV/AIDS|url=http://apps.who.int/medicinedocs/en/d/Js8112e/6.html|publisher=World Health Organization|accessdate=1 August 2015|date=2005}}</ref><ref>{{cite book|title=Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases|date=2014|publisher=Elsevier Health Sciences|isbn=9780323263733|page=2753|edition=8|url=https://books.google.ca/books?id=73pYBAAAQBAJ&pg=PA2753}}</ref>。在美國，十天的療程大約需花費26美元，美国食品和药物管理局建议它仅在必要时使用，因为它已被证明在小鼠和大鼠中是致癌的，以及处方的微生物，并且可以产生抗药性<ref name=AHFS2015/>。

== 參考文獻 ==
{{Reflist|30em}}

{{-}}
{{Chromalveolate antiparasitics}}
{{国家基本药物目录/抗寄生虫病药}}

[[Category:硝基咪唑抗生素|Category:硝基咪唑抗生素]]
[[Category:抗原虫药|Category:抗原虫药]]
[[Category:輝瑞產品|Category:輝瑞產品]]
[[Category:世界卫生组织基本药物|Category:世界卫生组织基本药物]]
[[Category:赛诺菲|Category:赛诺菲]]
[[Category:IARC第2B类致癌物质|Category:IARC第2B类致癌物质]]